Fig. 6

CDC20 promotes the response to immune checkpoint inhibitors and the activation of anti-tumor immunity through GSDME A The schematic graph of experimental design and the picture of xenografts after the sacrifice of mice. Mice bearing TRAMP-C2 tumors infected with the indicated lentiviral shRNA constructs were implanted 7 days earlier and treated with or without anti-PD1 monoclonal antibodies (5 mice per group). B The volume of xenografts in C57BL/6 mice bearing TRAMP-C2 tumors infected with the indicated lentiviral shRNA constructs with or without administering anti-PD1 monoclonal antibodies. C The tumor weight of xenografts after the sacrifice of indicated mice in A. D Flow cytometric analysis of the single cell suspension derived from TRAMP-C2 tumors in A. E Representative flow cytometric analysis figures indicate the difference between CD8⁺ and CD4⁺ T lymphocytes in TRAMP-C2 tumors implanted in C57BL/6 mice. F The immunohistochemistry staining for CD8 on TRAMP-C2 tumors implanted in C57BL/6 mice infected with the indicated lentiviral shRNA constructs with or without anti-PD1 monoclonal antibodies. G The quantification of F. H The schematic graph of experimental design and the picture of xenografts after the sacrifice of mice. Mice bearing TRAMP-C2 tumors implanted 7 days earlier were treated with or without the Cdc20 inhibitor, Apcin, or the anti-PD1 monoclonal antibodies (5 mice per group). I The volume of xenografts in C57BL/6 mice bearing TRAMP-C2 tumors with or without administering anti-PD1 monoclonal antibodies or Apcin J Xenografts’ tumor weight after the sacrificed indicated mice in H